Abstract: The present disclosure provides novel powder daptomycin formulations which have improved chemical stability and faster reconstitution times when in the solid state. Some examples of the compositions comprise daptomycin and sucrose.

Abstract: The invention relates to a wetting and dispersing agent that can be produced by carrying out step (1): wherein a) an organic polymer containing primary and/or secondary amino groups and b) at least one branched polyhydroxymonocarboxylic acid comprising, in addition to a carboxyl group, at least two hydroxy groups, one of which is not bound to the main chain of the molecule, are reacted by condensation reactions, forming amide linkages; and step (2): wherein at least some of the hydroxy groups of the hydroxy-functional reaction product obtained in step (1) are reacted with at least one organic monoisocyanate, forming urethane linkages.

Abstract: The present disclosure provides novel powder daptomycin formulations which have improved chemical stability and faster reconstitution times when in the solid state. Some examples of the compositions comprise daptomycin and sucrose.

Abstract: The present disclosure provides novel powder daptomycin formulations which have improved chemical stability and faster reconstitution times when in the solid state. Some examples of the compositions comprise daptomycin and sucrose.

Abstract: The present invention provides oral formulations of poorly bioavailable and/or poorly absorbable, and/or poorly water soluble therapeutic agents. The invention features harmaceutical composition including a biopolymer, a therapeutic agent, for example an antimicrobial agent such as ceftriaxone, and an absorption enhancer, for example a polyoxyethylene alkyl ether absorption enhancer. Methods of making and using the pharmaceutical compositions is also described.

Abstract: Provided are compositions and methods for stimulating immune responses against antigens. The compositions contain an antigen to which a stimulated immune response is desired and an isolated Prx1 protein. The Prx1 protein functions as an adjuvant so that the immune response to the antigen stimulated by the composition comprising the antigen and Prx1 is greater than the immune response stimulated by the antigen alone.

Abstract: The present invention provides oral formulations of poorly bioavailable and/or poorly absorbable, and/or poorly water soluble therapeutic agents. The invention features pharmaceutical composition including a biopolymer, a therapeutic agent, for example an antimicrobial agent such as ceftriaxone, and an absorption enhancer, for example a polyoxyethylene alkyl ether absorption enhancer. Methods of making and using the pharmaceutical compositions is also described.

Abstract: The present disclosure provides novel powder daptomycin formulations which have improved chemical stability and faster reconstitution times when in the solid state. Some examples of the compositions comprise daptomycin and sucrose.

Abstract: The invention relates to compositions comprising two structured linear copolymers selected from the group consisting of block copolymers and gradient copolymers, these copolymers being prepared by different controlled polymerization techniques and the difference in the polydispersities of these copolymers, ?(Mw/Mn), being ?0.25. The invention further relates to the production of such blends and to their use as wetting agents and dispersants.

Abstract: The present disclosure provides novel powder daptomycin formulations which have improved chemical stability and faster reconstitution times when in the solid state. Some examples of the compositions comprise daptomycin and sucrose.

Abstract: The present disclosure provides novel solid CB-183,315 formulations which have improved chemical stability. The chemical stability of the solid CB-183,315 is dependent on the process by which the composition is made. Solid preparations of CB-183,315 can be prepared by the following method: (a) forming an aqueous solution of CB-183,315 and at least one sugar that (e.g., sucrose, trehalose or dextran) at a pH of 2-7, preferably pH 6 and (b) converting the aqueous solution to the solid preparation of CB-183,315 (e.g., via lyophilization or spray drying).

Abstract: The invention relates to a wetting and dispersing agent that can be produced by carrying out step (1): wherein a) an organic polymer containing primary and/or secondary amino groups and h) at least one branched polyhydroxymonocarboxylic acid comprising, in addition to a carboxyl group, at least two hydroxy groups, one of which is not bound to the main chain of the molecule, are reacted by condensation reactions, forming amide linkages; and step (2): wherein at least some of the hydroxy groups of the hydroxy-functional reaction product obtained in step (1) are reacted with at least one organic monoisocyanate, forming urethane linkages.

Abstract: The present invention provides liquid formulations of antibodies or fragments thereof that specifically bind to a hepatitis B virus (HBV) antigen, which formulations exhibit stability, low to undetectable levels of aggregations, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. Furthermore, the invention provides methods of preventing, treating or ameliorating one or more symptoms associated with HBV infection utilizing the liquid formulations of the present invention.

Abstract: The present disclosure provides novel solid CB-183,315 formulations which have improved chemical stability. The chemical stability of the solid CB-183,315 is dependent on the process by which the composition is made. Solid preparations of CB-183,315 can be prepared by the following method: (a) forming an aqueous solution of CB-183,315 and at least one sugar that (e.g., sucrose, trehalose or dextran) at a pH of 2-7, preferably pH 6 and (b) converting the aqueous solution to the solid preparation of CB-183,315 (e.g., via lyophilization or spray drying).

Abstract: The present disclosure provides novel powder daptomycin formulations which have improved chemical stability and faster reconstitution times when in the solid state. Some examples of the compositions comprise daptomycin and sucrose.

Abstract: Provided are compositions and methods for stimulating immune responses against antigens. The compositions contain an antigen to which a stimulated immune response is desired and an isolated Prx1 protein. The Prx1 protein functions as an adjuvant so that the immune response to the antigen stimulated by the composition comprising the antigen and Prx1 is greater than the immune response stimulated by the antigen alone.

Abstract: Provided is a method for inhibiting angiogenesis in a tumor. The method involves administering to an individual who has a tumor a composition that contains an agent capable of inhibiting binding of peroxiredoxin 1 (Prx1) to Toll like receptor 4 (TLR4) such that angiogenesis in the tumor is inhibited subsequent to the administration. The agent that is capable of inhibiting binding of Prx1 to TLR4 can be an antibody to Prx1, a Prx1 binding fragment of the antibody, or a peptide. The peptide can be capable of inhibiting the formation of a Prx1 decamer, or can inhibit binding of Prx1 to TLR4 by steric interference, or by competitions with Prx1 for TLR4 binding. The tumor in which angiognesis is inhibited can be any type of cancer tumor.

Abstract: The present invention provides liquid formulations of antibodies or fragments thereof that specifically bind to a hepatitis B virus (HBV) antigen, which formulations exhibit stability, low to undetectable levels of aggregations, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. Furthermore, the invention provides methods of preventing, treating or ameliorating one or more symptoms associated with HBV infection utilizing the liquid formulations of the present invention.

Abstract: The present invention provides liquid formulations of antibodies or fragments thereof that specifically bind to a hepatitis B virus (HBV) antigen, which formulations exhibit stability, low to undetectable levels of aggregations, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. Furthermore, the invention provides methods of preventing, treating or ameliorating one or more symptoms associated with HBV infection utilizing the liquid formulations of the present invention.